NEWTON, Mass.--(BUSINESS WIRE)--Feb. 14, 2005--Clinical Data, Inc. (NASDAQ:CLDA) announced today that it has entered into a distribution agreement with Daiichi Pure Chemicals Co., Ltd., of Tokyo. Under this agreement Clinical Data will serve as the master distributor for a new diagnostic assay for the measurement of Prostate Specific Antigen or PSA, a marker for the presence of prostate cancer. Daiichi's unique and proprietary assay technology allows PSA to be measured on Clinical Data's existing line of clinical chemistry analyzers and on most conventional clinical chemistry systems currently in use around the world.